13 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Feb 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Feb 2027
Next term end
8
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2028 · Medium confidence
Also notable
Ends Jun 2038 · High confidence
Also notable
Ends Feb 2037 · High confidence
Stimulation Device Adapter
US 11,576,599
Cited by 11 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2028.
Nerve Regeneration System and Method
US 11,766,567
Cited by 7 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2038.
Percutaneous Stimulation Device and Method for Detecting Compartment Syndrome
US 10,433,785
Cited by 31 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Composition Comprising Chitosan for Use in the Prevention And/Or in the Treatment of Incontinence And/Or Impotence in a Subject Undergoing Prostatectomy (US 10,328,096) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Mar 26, 2027The maintenance fee for Nerve Regeneration System and Method (US 11,766,567) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 1 fee due Apr 8, 2027The maintenance fee for Percutaneous Stimulation Device and Method for Detecting Compartment Syndrome (US 10,433,785) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Nerve Regeneration Method (US 11,872,401) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
Recent changes
- Nov 1Assignment recorded on 1 record: Walker, Eric and 5 others to Checkpoint Surgical, Inc. Recorded Nov 1, 2026, executed Oct 27, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76587, frame 875.
- Nov 1Assignment recorded on 1 record: Scanlan, Kevin and 3 others to Checkpoint Surgical, Inc. Recorded Nov 1, 2026, executed Oct 27, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76587, frame 898.
What they patent
The 5 largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Nerve Regeneration Method | 3 in force | to Jun 2038 |
| Electrical Stimulation Device | 2 in force | to Jun 2041 |
| Percutaneous Stimulation Device and Method for Detecting Compartment Syndrome | 2 in force | to Feb 2037 |
| Systems and Methods for Intra-Operative Stimulation | 2 in force | to Jan 2028 |
| Chitosan Tubular Member and Method of Producing | 1 in force | to Aug 2043 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,896,815 | Systems and Methods for Intra-Operative Stimulation In force · High confidence | In force | High confidence | |
| US 11,576,599 | Stimulation Device Adapter In force · Medium confidence | In force | Medium confidence | |
| US 11,344,250 | Percutaneous Stimulation Device and Method for Detecting Compartment Syndrome In force · High confidence | In force | High confidence | |
| US 10,433,785 | Percutaneous Stimulation Device and Method for Detecting Compartment Syndrome In force · High confidence | In force | High confidence | |
| US 10,328,096 | Composition Comprising Chitosan for Use in the Prevention And/Or in the Treatment of Incontinence And/Or Impotence in a Subject Undergoing Prostatectomy In force · High confidence | In force | High confidence | |
| US D956,987 | Electrical Stimulation Device In force · High confidence | In force | High confidence | |
| US 11,766,567 | Nerve Regeneration System and Method In force · High confidence | In force | High confidence | |
| US 11,872,401 | Nerve Regeneration Method In force · High confidence | In force | High confidence | |
| US 12,311,178 | Nerve Regeneration System and Method In force · High confidence | In force | High confidence | |
| US D1,055,283 | Nerve Cutting Device In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 6 patents ended · 10 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.